UnknownNot Applicable

The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

South Korea45 participantsStarted 2012-06

Plain-language summary

To find the safe effective lowest light dose for photodynamic therapy (PDT). in the treatment of central serous chorioretinopathy.

Age range20 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Idiopathic detachment of the neurosensory retina with a focal leak at the level of the RPE with FA
✓. Presence of SRF and/or serous pigment epithelial detachment on optical coherence tomography (OCT)
✓. Presence of abnormal dilated choroidal vasculature in ICGA
✓. Patients with symptomatic CSC of at least 3 months duration

✕. Patients who received any previous treatment, including PDT or focal thermal laser photocoagulation for CSC, or who had evidence of CNV, PCV, or other maculopathy on clinical examination, FA, or ICGA
✕. Patients receiving exogenous corticosteroid treatment
✕. Patients with systemic diseases such as Cushing's disease or renal diseases
✕. Pregnant patients

Changes of best corrected visual acuity

Timeframe: 6 month

NCT IDNCT01630863

SponsorYeungnam University College of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-10

Min Sagong